ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2017

CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair.

T R Shenoy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.